Lobbying Filing Details

Total Spending

$1,260,000

Activities

5

Lobbyists

11

Gov't Entities

40

Filing Information
Filing UUID:
b74a1025-edca-4409-8edb-cf3f77440b7a
Type:
Q4 - 4th Quarter - Report
Period:
2020 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 20, 2021 at 10:34 PM
Income:
$0
Expenses:
$1,260,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

FDA Funding.
H.R.133: Consolidated Appropriations Act, 2021.

Lobbyists (5)
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Health & Human Services, Dept of (HHS)
  • Federal Trade Commission (FTC)
  • ... and 3 more
Activity 2
Copyright/Patent/Trademark

Patent Settlements.
Patent Abuse.
BPCIA Patent Dance.
Inter Partes Review.
H.R.4850/S.659: Biologic Patent Transparency Act.
Section 101 of the Patent Act.

Lobbyists (5)
  • CHRISTOPHER BOWLIN
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • DANIEL LEONARD
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Health & Human Services, Dept of (HHS)
  • Federal Trade Commission (FTC)
  • ... and 3 more
Activity 3
Medicare/Medicaid

Medicare Part D Program and Generic Drugs.
Medicare Reimbursement for Biosimilars.
Medicaid Rebate Penalty.
Medicare Part D Low Income Subsidy (LIS) Program.
Medicare Part D Coverage Gap Discount Program.
Medicare Shared Savings Program.

Lobbyists (8)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • KATHERINE RAAB
  • DANIEL LEONARD
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Health & Human Services, Dept of (HHS)
  • Federal Trade Commission (FTC)
  • ... and 3 more
Activity 4
Pharmacy

Implementation of Food and Drug Administration Reauthorization Act (FDARA).
FDA Inspections.
Consent to FDA Approval.
Generic Drug User Fee Amendments (GDUFA).
GDUFA III Negotiations.
Biosimilar User Fee Act (BsUFA).
BsUFA III Negotiations.
Biosimilar Insulin.
Labeling of Generic Drugs and Biosimilars.
S.1681: Advancing Education on Biosimilars Act of 2020.
Labeling Carve-Outs.
GSK v. Teva.
H.R.5668: MODERN Labeling Act of 2020.
S.1636: Ensuring Innovation Act.
Drug Shortages.
Stockpile of Generic Drugs.
H.R.7507: State Stockpile Readiness Act of 2020.
H.R.8479: Essential Medicines Strategic Stockpile Act of 2020.
Pass Through Payments for Biosimilars.
Cost Sharing for Biosimilars.
H.R.6179/S.4134: Increasing Access to Biosimilars Act of 2020.
H.R.4455: BIOSIM Act.
H.R.4597: Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R.4629: Star Rating for Biosimilars Act.
Prescription Drug Costs.
Drug Pricing.
Executive Order 13947/13948: Lowering Drug Prices by Putting America First.
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
180-Day Exclusivity.
Forfeiture of 180-Day Exclusivity.
12-Year Exclusivity.
S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019.
H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.
S.844: Short on Competition Act.
H.R.465/S.102: Prescription Drug Price Relief Act of 2019.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.8529: Protecting Access to Affordable Medicines Act of 2020.
S.3092: Expanding Access to Low-Cost Generics Act of 2019.
S.1895: Lower Health Care Costs Act.
Pharmaceutical Exclusivity.
H.R.8905: Supply Chain Security and Pharmaceutical Authentication Act of 2020.
S.659: Biologic Patent Transparency Act.
Biologics Price Competition and Innovation Act (BPCIA).
H.R.1503: Orange Book Transparency Act of 2020.
H.R.1520: Purple Book Continuity Act of 2020.
Issues Related to COVID-19.
Public Law No 116-136: Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Buy American Proposals.
Buy American Executive Order.

Lobbyists (11)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
  • KATHERINE RAAB
  • DANIEL LEONARD
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Health & Human Services, Dept of (HHS)
  • Federal Trade Commission (FTC)
  • ... and 3 more
Activity 5
Trade (domestic/foreign)

General Trade Issues.
Pharmaceutical Exclusivity.
Quality Supply Chain.
Drug Supply Chain.
Pharmaceutical Supply Chain.
AAM Blueprint to Enhance the Security of the U.S. Supply Chain.
Carter Supply Chain Legislation.
United States-Mexico-Canada Agreement (USMCA).
U.S.-UK Trade Agreement.
U.S.-China Trade Discussions.

Lobbyists (9)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • KATHERINE RAAB
  • DANIEL LEONARD
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Health & Human Services, Dept of (HHS)
  • Federal Trade Commission (FTC)
  • ... and 3 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.